CU CSCI Senior Project – Forge – Computer Science
Array BioPharma Inc. is a biopharmaceutical company with a focus on the discovery, development, and commercialization of targeted small molecule drugs, primarily for the treatment of cancer. Founded in 1998 by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou, Array BioPharma has made significant strides in the field of oncology medication.
Headquartered in Boulder, Colorado, the company has developed a range of clinical-stage drugs, including Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292, and LOXO-195. These drugs represent Array BioPharma’s commitment to advancing the treatment options available for various types of cancer.
Array BioPharma has been recognized for its innovative approach in developing targeted therapies for cancer treatment. The company’s work involves extensive research and development to create small molecule drugs that can effectively target specific types of cancer cells, potentially leading to more effective and less toxic treatments compared to traditional chemotherapy.
In a significant development for the company, Pfizer Inc., a global pharmaceutical giant, acquired Array BioPharma. This acquisition, announced by Pfizer, marked a milestone in the company’s history, indicating the value and potential of Array BioPharma’s research and development in cancer treatment. The acquisition by Pfizer is expected to further advance the science behind targeted small molecule medicines, not only for cancer but also for other diseases with high unmet medical needs.
Array BioPharma’s journey, from its establishment to its acquisition by Pfizer, highlights its important role in the pharmaceutical industry, particularly in the field of oncology, and underscores the ongoing need for innovative treatments in the fight against cancer.